Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

This study has been completed.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: September 25, 2012
Last updated: January 16, 2014
Last verified: January 2014

The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD.

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: Tiotropium
Drug: Placebo matching Olodaterol
Drug: Olodaterol
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • FEV1 AUC0-3h response at 12 weeks; defined as change from baseline to Week 12 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Trough FEV1 response at 12 weeks; defined as change from baseline to Week 12 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Saint George Respiratory Questionnaire-Total Score- Key secondary endpoint [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Peak FEV1 response at Week - defined as change from baseline [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • FVC AUC0-3h response at 12 - defined as change from baseline [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Trough FVC response at 12 weeks- defined as change from baseline [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Peak FVC response at 12 weeks- defined as change from baseline [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Rescue medication usage - two variables will be calculated for each patient; the number of rescue free days, and weekly mean use of rescue medications. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 1134
Study Start Date: September 2012
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Olodaterol and Tiotropium
2 puffs olodaterol from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
Drug: Olodaterol
One dose
Drug: Tiotropium
Marketed dose
Placebo and Tiotropium
2 puffs placebo inhalation solution from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
Drug: Tiotropium
Marketed dose
Drug: Placebo matching Olodaterol
One dose


Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. All patients must sign an informed consent consistent with International Conference on Harmonization-Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions.
  2. All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria: Patients must have a relatively stable airway obstruction with a post-bronchodilator FEV1 = 30 % and < 80% of predicted normal and a post-bronchodilator FEV1/FVC <70% at Visit 1.
  3. Male or female patients, 40 years of age or older.
  4. Patients must be current or ex-smokers with a smoking history of more than 10 pack years
  5. Patients must be able to: perform technically acceptable pulmonary function tests, and maintain records(paper diary).
  6. Patients must be able to inhale medication in a competent manner from the Respimat Inhaler as well as the Handihaler.

Exclusion criteria:

  1. Patients with a significant disease other than COPD; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patients ability to participate in the study.
  2. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an AST >x2 ULN, ALT >x2 ULN, bilirubin >x2 ULN or creatinine >x2 ULN will be excluded regardless of clinical condition (a repeat laboratory evaluation will not be conducted in these patients).
  3. Patients with a history of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma. If a patient has a total blood eosinophil count =600/mm3, source documentation is required to verify that the increased eosinophil count is related to a non-asthmatic condition.
  4. A diagnosis of thyrotoxicosis (due to the known class side effect profile of ß2-agonists).
  5. A diagnosis of paroxysmal tachycardia (>100 beats per minute) (due to the known class side effect profile of ß2-agonists).
  6. A history of myocardial infarction within 1 year of screening visit (Visit 1).
  7. Unstable or life-threatening cardiac arrhythmia.
  8. Hospitalization for heart failure within the past year.
  9. Known active tuberculosis.
  10. A malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed).
  11. A history of life-threatening pulmonary obstruction.
  12. A history of cystic fibrosis.
  13. Clinically evident bronchiectasis.
  14. A history of significant alcohol or drug abuse.
  15. Patients who have undergone thoracotomy with pulmonary resection (patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion No. 1).
  16. Patients being treated with oral or patch ß-adrenergics.
  17. Patients being treated with oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.
  18. Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigators opinion will be unable to abstain from the use of oxygen therapy during clinic visits.
  19. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program.
  20. Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to screening visit (Visit 1).
  21. Patients with known hypersensitivity to ß-adrenergic drugs, BAC, EDTA, or any other component of the Respimat® inhalation solution.
  22. Patients with known hypersensitivity to anticholinergic drugs, lactose, or any other components of the HandiHaler®.
  23. Pregnant or nursing women.
  24. Women of childbearing potential not using a highly effective method of birth control*. Female patients will be considered to be of childbearing potential unless surgically sterilised by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years.

    * as per ICH M3(R2) a highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year).

  25. Patients who have previously been randomised in this study or are currently participating in another study.
  26. Patients who are unable to comply with pulmonary medication restrictions prior to randomisation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01694771

  Show 90 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim Identifier: NCT01694771     History of Changes
Other Study ID Numbers: 1222.51
Study First Received: September 25, 2012
Last Updated: January 16, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 27, 2014